Agile Therapeutics, Inc. (AGRX) financial statements (2022 and earlier)

Company profile

Business Address 500 COLLEGE ROAD EAST
PRINCETON, NJ 08540-6635
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments19,14354,47134,4797,85135,95248,75034,395
Cash and cash equivalents19,14314,46334,4797,85135,95248,75034,395
Short-term investments 40,008     
Receivables1,533865     
Inventory, net of allowances, customer advances and progress billings966100     
Inventory966100     
Prepaid expense2,2831,4498406077622,7683,690
Other undisclosed current assets (100)     
Total current assets:23,92556,78535,3198,45836,71451,51838,085
Noncurrent Assets
Operating lease, right-of-use asset949138 
Property, plant and equipment12,44714,24314,04413,91613,86312,33012,318
Deferred costs      291
Other noncurrent assets2,0121,896 18181818
Other undisclosed noncurrent assets  177    
Total noncurrent assets:15,40816,27714,22113,93413,88112,34812,627
TOTAL ASSETS:39,33373,06249,54022,39250,59563,86650,712
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,2707,2153,6232,2183,6365,4025,040
Accounts payable8,7073,8671,8198752,7842,0502,387
Accrued liabilities3,5633,3481,8041,3438523,3522,653
Debt16,833 172 10,6075,1042,488
Derivative instruments and hedges, liabilities    29172406
Other undisclosed current liabilities175138     
Total current liabilities:29,2787,3533,7952,21814,27210,6787,934
Noncurrent Liabilities
Long-term debt and lease obligation784    10,89913,035
Long-term debt, excluding current maturities     10,89913,035
Operating lease, liability784  
Other undisclosed noncurrent liabilities(784)16,381     
Total noncurrent liabilities:78416,381   10,89913,035
Total liabilities:30,06223,7343,7952,21814,27221,57720,969
Stockholders' equity
Stockholders' equity attributable to parent9,27149,32845,74520,17436,32342,28929,743
Common stock12973332
Additional paid in capital396,376361,539306,108261,722258,092235,754194,468
Accumulated other comprehensive income 3     
Accumulated deficit(387,117)(312,223)(260,370)(241,551)(221,772)(193,468)(164,727)
Total stockholders' equity:9,27149,32845,74520,17436,32342,28929,743
TOTAL LIABILITIES AND EQUITY:39,33373,06249,54022,39250,59563,86650,712

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues4,101749     
Cost of revenue(10,718)(282)     
Gross profit:(6,617)467     
Operating expenses(64,388)(49,520)(18,858)(19,535)(26,811)(29,721)(33,089)
Operating loss:(71,005)(49,053)(18,858)(19,535)(26,811)(29,721)(33,089)
Nonoperating income (expense)(3,889)(2,800)252(721)(1,493)1175
Investment income, nonoperating253092523662821175
Interest and debt expense(3,914)(3,109) (1,116)(1,918)(2,446)(3,113)
Loss from continuing operations before equity method investments, income taxes:(78,808)(54,962)(18,606)(21,372)(30,222)(32,050)(36,197)
Other undisclosed income (loss) from continuing operations before income taxes 3,109 1,1161,918234(110)
Loss from continuing operations before income taxes:(78,808)(51,853)(18,606)(20,256)(28,304)(31,816)(36,307)
Income tax benefit   477 3,0755,972
Loss before gain (loss) on sale of properties:(78,808)(51,853)(18,606)(19,779)(28,304)(28,741)(30,335)
Other undisclosed net income3,914      
Net loss available to common stockholders, diluted:(74,894)(51,853)(18,606)(19,779)(28,304)(28,741)(30,335)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(74,894)(51,853)(18,606)(19,779)(28,304)(28,741)(30,335)
Comprehensive loss:(74,894)(51,853)(18,606)(19,779)(28,304)(28,741)(30,335)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3)3     
Comprehensive loss, net of tax, attributable to parent:(74,897)(51,850)(18,606)(19,779)(28,304)(28,741)(30,335)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: